Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

News

The latest news, research updates and announcements from the Nuffield Department of Medicine.

For media enquiries, background information on any of our research, or to arrange interviews with relevant scientists please contact Lucy Pritchard, NDM Head of Communications. We also have photos and videos of our work available for B-roll purposes.

Subscribe by RSS

What's new

COVID Moonshot delivers promising pre-clinical antiviral drug candidate

Centre for Medicines Discovery researchers, in partnership with the COVID Moonshot initiative and the AI-driven Structure-enabled Antiviral Platform (ASAP), have developed the first open-science coronavirus antiviral. This has been formally nominated as a broad-spectrum pre-clinical drug candidate by the Drugs for Neglected Diseases initiative (DNDi).

Oxford University to accelerate T1D research and care with £10m gift

The University of Oxford has announced a gift of £10 million from the Bukhman Foundation to support ground-breaking research into type 1 diabetes. This generous funding will establish the Bukhman Centre for Research Excellence in Type 1 Diabetes, as well as create new academic posts and scholarships, helping to accelerate progress towards better treatments and ultimately a cure.

Professor Xin Lu and Dr Ricardo Fernandes

NDM research teams shortlisted for Cancer Grand Challenges

Two research teams in the Nuffield Department of Medicine have been selected for the final stages of the Cancer Grand Challenges. This includes Professor Xin Lu at Ludwig Oxford in the Cancer Antibody Atlas team and Dr Ricardo Fernandes at the CAMS Oxford Institute as a co-investigator in a team led by the Weizmann Institute.

(L to R) Prof Grahame Ogg, Dr Yi-Ling Chen, Prof Andrew McMichael and Prof Tao Dong

Dr. Yi-Ling Chen (COI) awarded prestigious ERC Starting Grant

Dr. Yi-Ling Chen, COI Career Development Fellow, awarded a prestigious ERC Starting Grant to Investigate the Role of CD1c-reactive T Cells in Post-streptococcal Disease. The ERC Starting Grant supports early-career researchers with 2-7 years of experience since completion of their PhD, providing up to €1.5 million over five years to establish independent research teams and pursue high-risk, high-reward science.

New studies reveal optimal time intervals for COVID-19 vaccine boosters

Two new papers from scientists in the Nuffield Department of Medicine and other University of Oxford institutions have shown how the immune system reacts differently depending on the length of interval between vaccine doses.

Cancer researcher in a lab looking into a microscope

New research shows that pressure flips the switch on cancer cells

A new study published in Nature reveals that the mechanical environment surrounding a tumour can cause cancer cells to change their behaviour, triggering a switch from rapid growth to a more invasive, drug-resistant state.

Dr Lennard Lee and Mr Michael Bryan

Researchers granted AI supercomputing award to advance cancer vaccine work

A research team in the Nuffield Department of Medicine has been awarded access to one of the UK’s most powerful AI supercomputing facilities to advance cancer vaccine research.

Researchers develop first clinical practice guideline for tuberculous meningitis

Researchers from the Oxford University Clinical Research Unit (OUCRU) have played a leading role in developing the world’s first international clinical practice guideline for tuberculous meningitis, now published in The Lancet Infectious Diseases.

Chronic pain research breakthrough identifies promising drug target

For the first time, a team of researchers have identified a new genetic link to pain, offering a promising drug target to alleviate chronic pain.

Using AI to reclassify multiple sclerosis progression

Researchers in the Big Data Institute at the University of Oxford, together with MS experts from ten leading institutions across the world and drug developers from Novartis and Roche, have collaborated to develop an artificial intelligence (AI) model for reclassifying the progression of multiple sclerosis (MS). This model is based on the largest collection of clinical trial data (Novartis-Oxford MS dataset) from people living with MS.

Researchers identify a new role for platelets which could improve cancer detection

Researchers at Ludwig Cancer Research Oxford have recently published their findings exploring a new role for platelets, potentially offering a new way to improve cancer detection.

Severe nurse shortages in Kenya undermine newborn care, despite advancements

A multi-disciplinary study by KEMRI-Wellcome Trust, Harnessing Innovation in Global Health for Quality Care (HIGH-Q), has revealed how workforce issues influence the quality of care in newborn units. The research highlighted the effect of severe nurse staffing shortages in Kenyan hospitals as a major obstacle to providing quality care for newborns.

Using a microscope for cancer research in a lab

Study reveals liver problems may drive DNA build-up in sepsis patients

Researchers at NDM’s Centre for Human Genetics have discovered that cell-free DNA builds up in the blood of patients with sepsis because of impaired liver clearance. These findings show that investigating cell-free DNA could be a powerful tool for monitoring what happens in the body during sepsis.

Bubonic plague treatment proven highly effective and safe in global first

Researchers from the UK and Madagascar, in collaboration with Madagascar’s health services and national plague programme, have conducted the world’s first rigorous clinical trial of treatments for bubonic plague.

Scientists create first atlas showing cell interaction in lung fibrosis

In a collaborative new study, researchers have developed the first mathematically supported cellular map of lung tissue in idiopathic pulmonary fibrosis and uncovered key immune cell interactions that could explain why lungs fail to repair in this deadly disease with no known cure.

New research highlights need for global action to tackle noma disease

A new paper conducted by the Infectious Disease Data Observatory and the World Health Organization has revealed major gaps in research on noma, a severe and often fatal oral disease affecting children in low-resource settings. The review analysed 366 studies to provide a comprehensive foundation for future research and policy action.

WHO Collaborating Centre for Genomic Surveillance of AMR launched

Hosted by the Centre for Genomic Pathogen Surveillance at PSI, the new Centre will support efforts to tackle one of the most pressing global health challenges of our time - antimicrobial resistance.

Researchers discover new treatment pathway for breast cancer

In a new study from Tao Dong’s Group, researchers have found a way to harness strong immune responses in people with early-stage breast cancer – opening up new treatment options for those in more advanced stages.

OUCRU and HSPI sign MoU to advance health research collaboration

OUCRU and the Health Strategy and Policy Institute have signed a Memorandum of Understanding to promote joint research and evidence-based health policy. The agreement marks a significant step toward a long-term interdisciplinary collaboration.

Professor Teresa Lambe OBE, shows HRH the Duke of Gloucester around the Tissue Culture Room alongside PhD Student Jack Saunders whose research focuses on Crimean-Congo haemorrhagic fever

HRH The Duke of Gloucester visits Old Road Campus

His Royal Highness the Duke of Gloucester visited the University of Oxford this week to tour two of its leading medical research centres: the Clinical BioManufacturing Facility (CBF) and the laboratories of the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI), located on the University’s Old Road Campus.